MedPath

Amprenavir

Generic Name
Amprenavir
Drug Type
Small Molecule
Chemical Formula
C25H35N3O6S
CAS Number
161814-49-9
Unique Ingredient Identifier
5S0W860XNR
Background

Amprenavir is a protease inhibitor used to treat HIV infection.

Indication

用于高效抗逆转录病毒疗法（HAART）的组成药物。

Clinical Trials
Related News

Investigation of the Potential Pharmacokinetic Interaction Between Nevirapine, Abacavir and Amprenavir in HIV-1 Infected Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Naive Adults

Phase 1
Terminated
Conditions
HIV Infections
Interventions
First Posted Date
2014-07-08
Last Posted Date
2014-07-14
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
8
Registration Number
NCT02182765

Salvage Therapy With Amprenavir, Lopinavir and Ritonavir in HIV-Infected Patients in Virological Failure.

Phase 2
Completed
Conditions
HIV Infections
First Posted Date
2005-09-20
Last Posted Date
2005-09-20
Lead Sponsor
French National Agency for Research on AIDS and Viral Hepatitis
Target Recruit Count
100
Registration Number
NCT00196625

HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)

Phase 4
Completed
Conditions
HIV-Associated Lipodystrophy Syndrome
Cardiovascular Disease
First Posted Date
2005-09-19
Last Posted Date
2012-04-12
Lead Sponsor
Kirby Institute
Target Recruit Count
80
Registration Number
NCT00192660
Locations
🇦🇺

St. Vincent's Hospital, Sydney, New South Wales, Australia

Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients

Phase 2
Completed
Conditions
HIV Infections
First Posted Date
2003-03-21
Last Posted Date
2023-12-01
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
328
Registration Number
NCT00056641
Locations
🇺🇸

UT Southwestern, Dallas, Texas, United States

🇨🇦

Toronto General Hospital, Toronto, Ontario, Canada

🇩🇪

Boehringer Ingelheim Investigational Site, Stuttgart, Germany

and more 78 locations

Once-Daily Drug Regimen for HIV-Infected Patients

Phase 1
Completed
Conditions
Acquired Immunodeficiency Syndrome
HIV Infections
First Posted Date
2002-12-10
Last Posted Date
2008-03-04
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
25
Registration Number
NCT00001968
Locations
🇺🇸

National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland, United States

Comparing Standard-Dose Versus Adjusted-Dose Lopinavir/Ritonavir Therapy in HIV-Infected Persons With Drug Resistance

Phase 2
Completed
Conditions
HIV Infections
First Posted Date
2002-09-19
Last Posted Date
2011-03-01
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
118
Registration Number
NCT00046033
Locations
🇺🇸

Univ of Miami, Miami, Florida, United States

🇺🇸

Case Western Reserve Univ, Cleveland, Ohio, United States

🇺🇸

Univ of Texas, Galveston, Galveston, Texas, United States

and more 3 locations

Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

Completed
Conditions
HIV Infections
Interventions
Drug: darunavir/ritonavir dosage #1
Drug: TAF w/cobicistat
Drug: elvitegravir/cobicistat
Drug: darunavir/cobicistat
Drug: atazanavir/cobicistat
Drug: lopinavir/ritonavir dosage #1
Drug: atazanavir/ritonavir/tenofovir dosage #1
Drug: lopinavir/ritonavir dosage #2
Drug: indinavir/ritonavir dosage #1
Drug: atazanavir/ritonavir dosage #1
Drug: tipranavir/ritonavir
Drug: darunavir/ritonavir dosage #4
Drug: indinavir/ritonavir dosage #2
Drug: darunavir/ritonavir dosage #2
Drug: lopinavir/ritonavir dosage #3
Drug: lopinavir/ritonavir dosage #4
Drug: tenofovir/atazanavir/ritonavir dosage #2
Drug: atazanavir/ritonavir dosage #2
Drug: darunavir/ritonavir dosage #3
Drug: levoflaxacin
Drug: ethionamide/prothionamide
Drug: terizidone/cycloserine
Drug: para-aminosalicylic acid (PAS)
First Posted Date
2002-08-01
Last Posted Date
2022-07-22
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
1578
Registration Number
NCT00042289
Locations
🇺🇸

Usc La Nichd Crs, Los Angeles, California, United States

🇿🇦

Wits RHI Shandukani Research Centre CRS, Johannesburg, Gauteng, South Africa

🇺🇸

Boston Medical Center Ped. HIV Program NICHD CRS, Boston, Massachusetts, United States

and more 59 locations

Drug Interactions of Amprenavir and Efavirenz, in Combination With a Second Protease Inhibitor, in HIV-Negative Volunteers

Not Applicable
Completed
Conditions
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2021-11-01
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
90
Registration Number
NCT00005762
Locations
🇺🇸

Stanford CRS, Palo Alto, California, United States

🇺🇸

University of Colorado Hospital CRS, Aurora, Colorado, United States

🇺🇸

Indiana Univ. School of Medicine, Infectious Disease Research Clinic, Indianapolis, Indiana, United States

and more 5 locations

Four-Drug Combination Therapy With Zidovudine, Lamivudine, 1592U89 (Abacavir), and 141W94 (Amprenavir) in HIV-Infected Patients

Not Applicable
Completed
Conditions
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2015-05-15
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
25
Registration Number
NCT00006617
Locations
🇺🇸

Aaron Diamond AIDS Res Ctr, New York, New York, United States

A Study to Compare Two Anti-HIV Drug Combinations That Include Amprenavir in HIV-Infected Patients Who Have Failed Anti-HIV Drug Combinations That Did Not Include Amprenavir

Phase 2
Completed
Conditions
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2005-06-24
Lead Sponsor
Glaxo Wellcome
Target Recruit Count
100
Registration Number
NCT00002423
Locations
🇺🇸

IDC Research Initiative, Altamonte Springs, Florida, United States

🇺🇸

Georgetown Univ Med Ctr, Washington, District of Columbia, United States

🇺🇸

Kansas City AIDS Research Consortium, Kansas City, Missouri, United States

and more 5 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy